<PAGE> 1
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): SEPTEMBER 26, 2000
LEXICON GENETICS INCORPORATED
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C> <C>
DELAWARE 000-30111 76-0474169
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NUMBER)
</TABLE>
4000 RESEARCH FOREST DRIVE
THE WOODLANDS, TEXAS 77381
(ADDRESS OF PRINCIPAL eXECUTIVE
OFFICES AND ZIP CODE)
(281) 364-0100
(REGISTRANT'S TELEPHONE NUMBER,
INCLUDING AREA CODE)
================================================================================
<PAGE> 2
ITEM 5. OTHER EVENTS
We entered into a database access and license agreement with Bristol-Myers
Squibb Company on September 26, 2000. Bristol-Myers Squibb will have access
under the agreement to our LexVision(TM) database, which contains phenotypic
information derived from our gene knockout platform. Scientists use mouse
knockouts - in which genes are deleted, or "knocked out," of the mouse genome -
to determine which human gene products are valid targets for the discovery and
development of new medicines. Bristol-Myers Squibb will also have access to our
OmniBank library of more than 90,000 mouse embryonic stem cell clones derived
from our gene-trap technology.
The term of the agreement is five years, although either party may
terminate after three years. Under the agreement, we could receive between $15
million and $25 million in access and delivery fees, in addition to milestones
and royalties on products Bristol-Myers Squibb develops using our technology.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
----------- -----------
<S> <C>
+10.1 -- LexVision(TM) Database and Collaboration Agreement,
dated September 26, 2000, between Lexicon Genetics
Incorporated and Bristol-Myers Squibb Company.
</TABLE>
---------------------
+ Confidential treatment has been requested for a portion of this
exhibit. The confidential portions of this exhibit have been omitted
and filed separately with the Securities and Exchange Commission.
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
LEXICON GENETICS INCORPORATED
Date: October 10, 2000 By: /s/ JEFFREY L. WADE
------------------------------
Jeffrey L. Wade
Executive Vice President and
General Counsel
3
<PAGE> 4
INDEX TO EXHIBITS
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
----------- -----------
<S> <C>
+10.1 -- LexVision(TM) Database and Collaboration Agreement,
dated September 26, 2000, between Lexicon Genetics
Incorporated and Bristol-Myers Squibb Company.
</TABLE>
---------------------
+ Confidential treatment has been requested for a portion of this
exhibit. The confidential portions of this exhibit have been omitted
and filed separately with the Securities and Exchange Commission.
